Adverum Biotechnologies Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$1.11 |
Market Cap |
$775.58 M |
Shares Outstanding |
63.78 M |
Public Float |
46.37 M |
Address |
1035 O'Brien Drive Menlo Park California 94025 United States |
Employees | - |
Website | http://www.adverum.com |
Updated | 07/08/2019 |
Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. |